Evaxion Biotech A/S (NASDAQ:EVAX) versus SAB Biotherapeutics (NASDAQ:SABS) Head-To-Head Review

Evaxion Biotech A/S (NASDAQ:EVAX) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, analyst recommendations, earnings, valuation and risk.

Institutional & Insider Ownership

11.0% of Evaxion Biotech A/S shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 41.6% of Evaxion Biotech A/S shares are held by company insiders. Comparatively, 26.5% of SAB Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Evaxion Biotech A/S and SAB Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evaxion Biotech A/S	-347.83%	N/A	-79.40%
SAB Biotherapeutics	-1,450.14%	-94.37%	-67.26%

Risk & Volatility

Evaxion Biotech A/S has a beta of -0.23, meaning that its share price is 123% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Evaxion Biotech A/S and SAB Biotherapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion Biotech A/S	0	0	2	0	3.00
SAB Biotherapeutics	0	0	5	0	3.00

Evaxion Biotech A/S currently has a consensus price target of $55.00, indicating a potential upside of 1,679.94%. SAB Biotherapeutics has a consensus price target of $12.40, indicating a potential upside of 251.27%. Given Evaxion Biotech A/S’s higher probable upside, research analysts clearly believe Evaxion Biotech A/S is more favorable than SAB Biotherapeutics.

Earnings & Valuation

This table compares Evaxion Biotech A/S and SAB Biotherapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion Biotech A/S	$70,000.00	259.12	-$22.12 million	($0.29)	-10.66
SAB Biotherapeutics	$2.24 million	14.55	-$42.19 million	N/A	N/A

Evaxion Biotech A/S has higher earnings, but lower revenue than SAB Biotherapeutics.

Summary

Evaxion Biotech A/S beats SAB Biotherapeutics on 7 of the 11 factors compared between the two stocks.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing – human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.